Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Home Depot

Pfizer

Walmart

Dividend stocks could be worth paying attention to as the Federal Reserve may look to pull back its monetary support.

Best Stocks To Buy Today? 4 Dividend Stocks To Check Out

ABBOTT PARK, Ill., Nov. 3, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, education, and improving the clinical research infrastructure within the U.S. This effort builds on Abbott's commitment of engaging populations who have historically been under-represented in medical research and will improve health by increasing access to innovative treatment options available within the trials process and increasing insights around how different groups respond to new therapies.

Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations

Boston Scientific

Canopy Growth

Quest Diagnostics

Henry Schein

IDEXX Laboratories

Insulet

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

4 Medical Products Stocks Poised to Beat This Earnings Season

Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Abbott (ABT): Will It Gain?

Is (ABT) Outperforming Other Medical Stocks This Year?

Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?

Palantir Technologies

Both are great places to park your money for years.

Got $5,000? These 2 Unstoppable Stocks Are No-Brainer Buys

Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.

Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases

There was nothing but good news for Abbott in Q3.

3 Things Investors Should Love About Abbott's Q3 Results

All four of the company's divisions posted strong growth, but one in particular was a standout.

Why Abbott Laboratories Shot Higher Today

On Wednesday, Abbott Laboratories (NYSE:ABT) shares surged nearly 4% after announcing solid fiscal third-quarter results. The company reported its most recent quarterly revenue and earnings before markets opened, beating the consensus Street expectations.

Is it too late to buy Abbott shares after raising FY2021 earnings guidance?

Abbott Laboratories (ABT) CEO Robert Ford on Q3 2021 Results - Earnings Call Transcript

NextEra Energy

Tesla

Verizon

Pre-Markets Opens Flat

Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up

Biogen

Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including the hit Korean television show “Squid Game,” which helped bring in new subscribers.

Abbot Labs and Biogen Outshine Novavax in the Health Care Sector

Abbott (ABT) delivered earnings and revenue surprises of 52.17% and 15.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Q3 Earnings and Revenues Beat Estimates

Abbott Laboratories (NYSE: ABT) is trading higher Wednesday after the company announced better-than-expected third-quarter financial results and raised guidance.  Abbott reported quarterly earnings of $1.40 per share, which beat the estimate of 94 cents per share.

Why Abbott Shares Are Rising Today

The stock price of Abbott Laboratories (NYSE: ABT) increased by over 4% during intraday trading today. This is why it happened.

ABT Stock: Why The Price Increased Today

Abbott Laboratories (NYSE: ABT) reported a 70.5% rise in quarterly profit to $2.1 billion, helped by strength in its medical devices and diagnostics businesses due to a rebound in COVID-19 test sales amid the spread of the Delta variant of the coronavirus. Abbott reported an adjusted EPS of $1.40, beating the consensus estimate of $0.94.

Abbott's Q3 Profit Jumps 70% On Robust COVID-19 Test Sales

Abbott reported an adjusted profit of $1.40 a share, beating forecasts for $0.94 a share.

Abbott Labs Earnings Beat Estimates. Its Stock Is Rising.

Shares of Abbott Laboratories ABT, +2.16% rallied 2.8% in premarket trading Wednesday, after the health care company reported third-quarter profit and sales that rose well above expectations, with the strongest growth seen in its diagnostics business, and provided an upbeat full-year outlook. Net income rose to $2.52 billion, or $1.17 a share, from $1.76 billion, or 69 cents a share, in the year-ago period.

Abbott Laboratories stock surges after big profit and sales beats, and upbeat full-year outlook

(Reuters) -Abbott Laboratories raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant.

Abbott raises annual profit forecast after upbeat quarterly results

ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance

Applied Materials

Comcast

D.R. Horton

Gaming and Leisure Properties

Intel

Johnson & Johnson

Lowe's

Mastercard

UnitedHealth Group

Visa

Xilinx

Kiplinger Investing publishes opportune source lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published on 6/1/21 and 9/9/21.

October Billionaire Update: 37 Stocks; 20 Dividends; 1 Buy

Abbott Laboratories(NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.

Abbott Laboratories's Earnings Outlook

Abbott Labs has dipped from its recent highs near $130 and presents a buying opportunity under $120.

News for Abbott Labs Stock (ABT)